Inflammatory ratios derived from peripheral blood cell counts across human diseases: current evidence and challenges in defining cut-off values
Inflammatory responses involve dynamic interactions among circulating immune and non-immune cells, including neutrophils, lymphocytes, monocytes, and platelets. Peripheral blood cell-derived inflammatory indices, particularly the neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), monocyte-to-lymphocyte ratio (MLR), and systemic immune-inflammation index (SII), have gained increasing attention as readily accessible composite markers of systemic inflammatory and immune alterations. Growing evidence links these indices with disease severity, treatment response, and clinical outcomes across cardiovascular, malignant, autoimmune, infectious, and metabolic diseases. However, their translation into routine clinical practice remains limited by the absence of robust, externally validated, and transferable cut-off values. Reported thresholds vary substantially according to disease type and stage, patient characteristics, clinical endpoints, preanalytical and analytical conditions, and the statistical approaches used for cut-off derivation. This narrative review draws on English-language literature identified through searches of PubMed, ScienceDirect, and Google Scholar conducted between March 18 and October 19, 2026, with publications selected for their relevance to the biological basis, clinical applications, and methodological challenges of peripheral blood cell-derived inflammatory indices. It examines the biological basis of these indices, with particular emphasis on relevant cellular interactions and inflammatory signaling pathways, summarizes current evidence across major disease categories, and critically evaluates the biological, clinical, analytical, and methodological factors contributing to cut-off variability and limiting the establishment of reliable clinical decision thresholds. We further consider whether universal cut-off values are biologically and clinically justified and propose that context-specific, endpoint-specific, and externally validated thresholds may provide a more appropriate framework for clinical implementation.
Authors
- Katarzyna Kwiatkowska (ORCID: https://orcid.org/0000-0003-2149-2350)
- Jonas Jurgaitis (ORCID: https://orcid.org/0000-0003-3208-5697)
- Barbara Ciastek
Institutions
- University of Opole (PL)
- Nicolaus Copernicus University (PL)
- Klaipėda University (LT)
- Republic Klaipeda Hospital (LT)
- Jan Biziel University Hospital No. 2 in Bydgoszcz (PL)
Publication Details
- Journal
- Frontiers in Cell and Developmental Biology
- Published
- 2026-11-16
- DOI
- https://doi.org/10.3389/fcell.2026.2010268
- Primary Topic
- Inflammatory Biomarkers in Disease Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00